Document is current
Any future updates will be listed below
-
Authors
Leslie, W. D.
Shevroja, E.
Johansson, H.
McCloskey, E. V.
Harvey, N. C.
Kanis, J. A.
Hans, D.
- License Information
-
More Information
Article History
Received: 2 October 2017
Accepted: 22 January 2018
First Online: 1 February 2018
Compliance with ethical standards
:
: Eugene McCloskey: Nothing to declare for FRAX and the context of this paper, but numerous ad hoc consultancies/speaking honoraria and/or research funding from Amgen, Bayer, General Electric, GSK, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UBS, and Warner-Chilcott.Didier Hans: Co-ownership in the TBS patent. Stock options or royalties: Med-Imaps. Research grants: Amgen, Radius Pharma, Agnovos, GE Healthcare.Nicholas Harvey: Nothing to declare for FRAX and the context of this paper but has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Radius, Consilient Healthcare, and Internis Pharma.John A. Kanis: Grants from Amgen, grants from Lilly, non-financial support from Medimaps, grants from Unigene, nonfinancial support from Asahi, grants from Radius Health, outside the submitted work; and Dr. Kanis is the architect of FRAX but has no financial interest. Governmental and NGOs: National Institute for health and clinical Excellence (NICE), UK; International Osteoporosis Foundation; INSERM, France; Ministry of Public Health, China; Ministry of Health, Australia; Ministry of Health, Abu Dhabi; National Osteoporosis Guideline Group, UK; WHO.
